![]() Dicloxacillin sodium structure
|
Common Name | Dicloxacillin sodium | ||
---|---|---|---|---|
CAS Number | 13412-64-1 | Molecular Weight | 510.323 | |
Density | N/A | Boiling Point | 692.4ºC at 760mmHg | |
Molecular Formula | C19H18Cl2N3NaO6S | Melting Point | 222-225°C | |
MSDS | Chinese USA | Flash Point | 372.5ºC | |
Symbol |
![]() ![]() GHS07, GHS08 |
Signal Word | Danger |
Use of Dicloxacillin sodiumDicloxacillin NaOH is a narrow-spectrum β-Lactam antibiotic of the penicillin class, is used to treat infections caused by susceptible Gram-positive bacteria, active against beta-lactamase-producing organisms such as Staphylococcus aureus. |
Name | dicloxacillin sodium monohydrate |
---|---|
Synonym | More Synonyms |
Description | Dicloxacillin NaOH is a narrow-spectrum β-Lactam antibiotic of the penicillin class, is used to treat infections caused by susceptible Gram-positive bacteria, active against beta-lactamase-producing organisms such as Staphylococcus aureus. |
---|---|
Related Catalog |
Boiling Point | 692.4ºC at 760mmHg |
---|---|
Melting Point | 222-225°C |
Molecular Formula | C19H18Cl2N3NaO6S |
Molecular Weight | 510.323 |
Flash Point | 372.5ºC |
Exact Mass | 509.019104 |
PSA | 150.10000 |
LogP | 2.13190 |
Storage condition | 2-8°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
![]() ![]() GHS07, GHS08 |
---|---|
Signal Word | Danger |
Hazard Statements | H315-H319-H334-H335 |
Precautionary Statements | P261-P284-P304 + P340-P305 + P351 + P338-P342 + P311 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
Hazard Codes | Xn: Harmful; |
Risk Phrases | R36/37/38 |
Safety Phrases | S22-S26-S36/37-S45 |
RIDADR | NONH for all modes of transport |
WGK Germany | 2 |
RTECS | XH8925000 |
HS Code | 2941109900 |
HS Code | 2941109900 |
---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Chem. Res. Toxicol. 23 , 1215-22, (2010) Drug-induced liver injury is a major issue of concern and has led to the withdrawal of a significant number of marketed drugs. An understanding of structure-activity relationships (SARs) of chemicals ... |
|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug Metab. Dispos. 38 , 2302-8, (2010) Drug-induced liver injury (DILI) is one of the most important reasons for drug development failure at both preapproval and postapproval stages. There has been increased interest in developing predicti... |
|
Gingival pain: an unusual side effect of ziprasidone.
BMJ Case Rep. 2013 , doi:10.1136/bcr-2012-007577, (2013) The patient is a 52-year-old man with schizophrenia who developed severe, unremitting gingival pain after his ziprasidone dosage was increased from 80 to 120 mg. His physical examination and laborator... |
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-, monosodium salt, monohydrate |
Dicloxacillin sodium salt monohydrate |
Dicloxacillin sodium |
MFCD00210902 |
Sodium 6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate hydrate (1:1:1) |
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl]carbonyl]amino]-3,3-dimethyl-7-oxo-, sodium salt, hydrate (1:1:1) |
EINECS 206-444-3 |
Dicloxacillin (Sodium hydrate) |